HCP Live

Lupus Treatment Advances: Agents in the Pipeline

Mar 31, 2022

Novel therapies in the pipeline that demonstrate potential advantages when used as treatment for systemic lupus erythematosus and lupus nephritis.

Related Videos

Brian LaMoreaux, MD | Credit: Horizon Therapeutics

Related Content

Risankizumab Provides Durable Quality of Life Improvements out to 100 Weeks in Psoriatic Arthritis

Relatable Rheumatology: Making the Invisible Visible Using Patient-Reported Outcomes in Research

Psoriatic Arthritis Linked to Increased Vascular Inflammation, Regardless of Disease Activity

Introducing the Relatable Rheumatology: From Stories to Studies Podcast

Report: For US Patients, Gout Burden Greatest Among Asian Americans

BE VITAL: Bimekizumab Helps Control, Attenuate Disease Activity in Psoriatic Arthritis

Risankizumab Provides Durable Quality of Life Improvements out to 100 Weeks in Psoriatic Arthritis

Relatable Rheumatology: Making the Invisible Visible Using Patient-Reported Outcomes in Research

Psoriatic Arthritis Linked to Increased Vascular Inflammation, Regardless of Disease Activity

Introducing the Relatable Rheumatology: From Stories to Studies Podcast

Report: For US Patients, Gout Burden Greatest Among Asian Americans

BE VITAL: Bimekizumab Helps Control, Attenuate Disease Activity in Psoriatic Arthritis

Risankizumab Provides Durable Quality of Life Improvements out to 100 Weeks in Psoriatic Arthritis

Relatable Rheumatology: Making the Invisible Visible Using Patient-Reported Outcomes in Research

Psoriatic Arthritis Linked to Increased Vascular Inflammation, Regardless of Disease Activity

Introducing the Relatable Rheumatology: From Stories to Studies Podcast

Report: For US Patients, Gout Burden Greatest Among Asian Americans

BE VITAL: Bimekizumab Helps Control, Attenuate Disease Activity in Psoriatic Arthritis

Related Content

Lars Erik Kristensen, MD, PhD | Credit: Parker Insitute

Risankizumab Provides Durable Quality of Life Improvements out to 100 Weeks in Psoriatic Arthritis

Relatable Rheumatology: Making the Invisible Visible Using Patient-Reported Outcomes in Research

Relatable Rheumatology: Making the Invisible Visible Using Patient-Reported Outcomes in Research

Nienke Kleinrensink, MSc | Credit: LinkedIn

Psoriatic Arthritis Linked to Increased Vascular Inflammation, Regardless of Disease Activity

Introducing the Relatable Rheumatology: From Stories to Studies Podcast

Introducing the Relatable Rheumatology: From Stories to Studies Podcast

Natalie McCormick, PhD | Credit: LinkedIn

Report: For US Patients, Gout Burden Greatest Among Asian Americans

Professor Ian McInnes | Credit: University of Glasgow

BE VITAL: Bimekizumab Helps Control, Attenuate Disease Activity in Psoriatic Arthritis

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.